KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets
DALLAS, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC
PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.)
(KALY) (“KALYâ€) today released a corporate
update that includes the latest on KALY’s developments with
Puration, Inc, (PURA) (“PURAâ€) and Generex
Biotechnology, Inc. (GNBT), the company’s
research on treatments for Chronic Obstructive Pulmonary
Disease (COPD), and other updates. The comprehensive update is
included in its entirety below:
Overview
Kali-Extracts, Inc. (“KALYâ€) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing its patented cannabis
extraction process to develop numerous wellness products both
internally and through partnerships. Similarly, KALY is utilizing
its patented cannabis extraction technology to develop
pharmaceutical products internally and through partnerships.
Puration, Inc. (PURA)
KALY has licensed its extraction process to PURA for
the production of beverages. With over $1 million in trailing
twelve-month sales, PURA’s sales of EVERx CBD Sports Water are
growing. KALY is now working with PURA to formulate a 25 MG
CBD formula for a new CBD infused water product. Together,
PURA and KALY have signed over a $1 million agreement to produce
CBD infused water for Generex Biotechnology, Inc. (GNBT). The GNBT product is expected to be on
shelves soon.
Hemp4mula
KALY has introduced its own line of CBD infused
candies under the name Hemp4mula. KALY has signed its first
distribution agreement for Hemp4mula gum and initiated the
production of Hemp4mula gummies. Hemp4mula gum will be on
retail shelves soon and for sale on line soon.
Pharmaceuticals
Prior to KALY’s recent acquisition of NCM Biotech
(NCM), NCM had conducted numerous trials on various treatment
applications of extracts derived from their patented extraction
process. KALY recently disclosed having completed an in vitro
genomics study to evaluate the impact of its pharmaceutical grade
cannabis extracts in combination with other therapies on Chronic
Obstructive Pulmonary Disease (COPD) patients. Favorable
results prompted the launch of a physiological study whose results
will be released later this quarter. The World Health Organization
estimates 65 million people worldwide are afflicted with moderate
to severe COPD and GlobalData forecasts that the COPD treatment
market will reach $14.1 billion by 2025. Other tests for
other diseases to include cancer, have been conducted utilizing
extracts from KALY’s patented extraction process.
Shareholders can expect to see results from these various tests to
be forthcoming soon in addition to next steps to advance the
various potential treatments to production. KALY is actively
working to develop partnerships with established, brand name
pharmaceutical companies, to accelerate the further development of
cannabis extract treatments.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459
